Non Alcoholic Fatty Liver Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Non Alcoholic Fatty Liver Disease stocks.

Non Alcoholic Fatty Liver Disease Stocks Recent News

Date Stock Title
Nov 21 GNFT Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions
Nov 20 IVA Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Nov 20 IVA Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
Nov 20 VKTX Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
Nov 19 VKTX Viking phase 2b study of NASH candidate hits primary endpoint
Nov 19 VKTX Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Nov 19 TERN Top 3 Health Care Stocks You'll Regret Missing In Q4
Nov 18 PLRX Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Nov 18 TERN Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Nov 18 SGMT Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Nov 18 SGMT Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.
Nov 18 VKTX 3 Things You Need to Know if You Buy Viking Therapeutics Today
Nov 18 IVA The first MASH drug could open the door for others — including GLP-1s
Nov 17 VKTX Is It Too Late to Buy Viking Therapeutics Stock?
Nov 16 VKTX Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Nov 15 IVA Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Nov 15 VKTX Market Whales and Their Recent Bets on VKTX Options
Nov 15 ETNB 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
Nov 15 VKTX Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Non Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver, causing inflammation and damage. It is the most common form of liver disease in the United States, affecting up to 25% of the population. NAFLD is closely linked to obesity, diabetes, and high cholesterol, and can lead to serious complications such as cirrhosis and liver cancer. Treatment typically involves lifestyle changes such as weight loss, exercise, and a healthy diet.

Browse All Tags